• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Instil Bio Inc.

    4/2/24 4:36:49 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TIL alert in real time by email
    SC 13G 1 til13g.htm


    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.     )*

     Instil Bio Inc
    (Name of Issuer)
     
    Common Stock, $0.000001 par value per share
    (Title of Class of Securities)
     
    45783C101
    (CUSIP Number)
     
    March 22, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     BML Investment Partners, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     346,190
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     346,190
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     346,190
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     5.3
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     PN
     
     
     
     
     




    Item 1(a). Name of Issuer:

    Instil Bio, Inc.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

     3963 Maple Avenue, Suite 350, Dallas, Texas 75219

    Item 2(a). Name of Person Filing:

      BML Investment Partners, L.P.

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     65 E Cedar - Suite 2, Zionsville, IN 46077

    Item 2(c). Citizenship:

     Delaware

    Item 2(d). Title of Class of Securities:

     Common Stock, $0.000001 par value per share
     
    Item 2(e). CUSIP Number:

     45783C101


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) Amount beneficially owned: 346,190


    (b) Percent of class:5.3%


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote:0


    (ii) Shared power to vote or to direct the vote:346,190

      (iii) Sole power to dispose or to direct the disposition of:0

      (iv) Shared power to dispose or to direct the disposition of:346,190
     


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    n/a
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     n/a

    Item 8. Identification and Classification of Members of the Group.

     n/a

    Item 9. Notice of Dissolution of Group.

     n/a
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: April 2, 2024
     
     
    BML Capital Management, LLC
     
     
    By:
     /s/ Braden M Leonard
       
    Name:  Braden M Leonard
       
    Title:  Managing Member
     
     

    Footnote:  BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     

    Get the next $TIL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TIL

    DatePrice TargetRatingAnalyst
    1/7/2025$11.00 → $52.00Hold → Buy
    Jefferies
    1/7/2025$11.00 → $52.00Hold → Buy
    Truist
    11/4/2024Mkt Perform
    JMP Securities
    4/12/2024$5.00 → $11.00Buy → Hold
    Jefferies
    11/1/2022$16.00 → $6.00Buy → Hold
    Truist
    11/1/2022Outperform → Market Perform
    Cowen
    8/13/2021$34.00Outperform
    Robert W. Baird
    8/13/2021$34.00Outperform
    Baird
    More analyst ratings

    $TIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Instil Bio upgraded by Jefferies with a new price target

      Jefferies upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously

      1/7/25 8:29:55 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio upgraded by Truist with a new price target

      Truist upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously

      1/7/25 8:29:34 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Instil Bio

      JMP Securities initiated coverage of Instil Bio with a rating of Mkt Perform

      11/4/24 7:41:54 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

      US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the clearance of an Investigational New Drug (IND) application for AXN-2510 ("'2510") by the U.S. Food and Drug Administration. Instil expects to initiate a phase 1 trial of ‘2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025. The trial i

      7/2/25 6:00:00 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

      DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Instil's wholly-owned subsidiary dedicated to the development of AXN-2510 ("'2510"), a potentially best-in-class PD-L1xVEGF bispecific antibody for solid tumors prioritizing front-line non-small cell lung cancer (NSCLC). "John's appointment reflects our commitment to assembling world-class leadership to maximize the value of the ‘2510 program for patients and shareholders, and we have benefited greatly fr

      6/11/25 7:00:22 AM ET
      $ALNY
      $TIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

      DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman brings deep experience in oncology drug development and other therapeutic areas, and a track record of leading programs through all phases of development, regulatory approval and commercialization. Bronson Crouch, CEO of Instil, stated, "We are thrilled to welcome Dr. Freedman as Chief Medical Officer. Jamie's extensive experience and leadership in biopharmaceutical R&D will be a tremendous asset in adva

      6/2/25 7:00:00 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    SEC Filings

    See more
    • Instil Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Instil Bio, Inc. (0001789769) (Filer)

      5/28/25 5:16:42 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Instil Bio, Inc. (0001789769) (Filer)

      5/27/25 5:03:44 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Instil Bio, Inc. (0001789769) (Filer)

      5/22/25 6:02:42 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Leadership Updates

    Live Leadership Updates

    See more
    • Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

      DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman brings deep experience in oncology drug development and other therapeutic areas, and a track record of leading programs through all phases of development, regulatory approval and commercialization. Bronson Crouch, CEO of Instil, stated, "We are thrilled to welcome Dr. Freedman as Chief Medical Officer. Jamie's extensive experience and leadership in biopharmaceutical R&D will be a tremendous asset in adva

      6/2/25 7:00:00 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineered TIL therapy using CoStAR Platform, with plans to share clinical data in 2023 Appointment of cell therapy pioneer Dr. Robert Hawkins as Head of Research and Development, and resignation of Chief Medical Officer, Dr. Zachary Roberts Company confirms cash runway into 2025 with anticipated sale-leaseback transaction of its Tarzana manufacturing facility DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("

      11/14/22 4:07:40 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer

      DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Tim Moore to the role of Chief Operating Officer. Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations, including at Genentech, Kite and most recently PACT Pharma. From 2016 to 2019, Mr. Moore was Executive Vice President, Technical Operations at Kite Pharma, where he was responsible for technical operations and successfully launched Yescarta®, one of the fi

      9/6/22 7:00:00 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      11/14/24 6:59:16 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      11/14/24 5:48:56 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      10/25/24 9:42:03 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Binder Gwendolyn

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      5/29/25 7:13:10 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gibson Neil W

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      5/29/25 7:12:03 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Matcham George

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      5/29/25 7:10:47 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care